9/13/2021

PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022

10 clinical sites selected to participate in the FDA Phase 2 clinical study evaluating ketamine for the treatment of Parkinson’s Disease
Initiated investigational new drug (IND) application to proceed to a Phase 2 clinical study for KETABET™ to treat depression
Completed Phase 2 clinical study protocol for ketamine to treat ALS for IND submission to the FDA
Near completion of research programs to advance novel microneedle patches for the delivery of psychedelics
Selected U.S.-based CDMO to develop and supply proprietary ketamine products for FDA Phase 3 clinical studies and commercialization
Positioned ketamine focused product pipeline for potential Phase 3 clinical studies and commercial supply in 2022

9/9/2021

PharmaTher to Present at H.C. Wainwright 23rd Annual Global Investment Conference

To provide an update on PharmaTher’s product pipeline and upcoming milestones on its FDA Phase 2 clinical studies and microneedle patch programs involving ketamine and psychedelics

9/7/2021

PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021

TORONTO, September 7, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released business highlights and financial results for its fiscal year ended May 31, 2021. Unless otherwise indicated, all amounts in this press release are in Canadian dollars.

8/4/2021

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis

Focusing on becoming a global leader in prescription-based ketamine products
Advancing to a Phase 2 clinical study in the U.S.

TORONTO, August 4, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease.

7/21/2021

PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

Strengthens position to become a leader in the intradermal delivery of FDA prescription-based ketamine products
Supports commercializing novel uses and delivery methods of psychedelics

6/28/2021

PharmaTher To Participate in Grizzle Psychedelics Con

TORONTO, June 28, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Fabio Chianelli, Chief Executive Officer, will participate in the Grizzle Psychedelics Con today at 12 PM ET.

6/16/2021

PharmaTher To Present At The H.C. Wainwright Psychedelics In Psychiatry And Beyond Virtual Conference

TORONTO, June 16, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Fabio Chianelli, Chief Executive Officer, will be presenting at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17, 2021.

6/15/2021

PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression

Potential for FDA 505(b)(2) regulatory pathway approval and FDA Fast Track designation
Advancing Ketamine and KETABET™ alone or in a microneedle patch for intradermal administration
Potential next generation treatment for mental health, neurological and pain disorders

6/10/2021

PharmaTher Provides Research and Development Update and Milestones for 2021

TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to provide an update on the research and development initiatives of its psychedelic product programs and upcoming milestones for 2021

6/1/2021

PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery Technology for Psychedelics and Antivirals

TORONTO, June 1, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company and TSRL, Inc. (“TSRL”), a company focused on developing microneedle patches for the delivery of antivirals for the treatment of influenza, are pleased to announce that PharmaTher and TSRL (collectively the “Companies”) entered into a Co-Development Agreement to jointly develop a microneedle array patch with the aim to control the manufacturing and supply of microneedle patches for the Companies respective clinical and commercial drug programs.

Press Releases